ADC Therapeutics SA - Asset Resilience Ratio
ADC Therapeutics SA (ADCT) has an Asset Resilience Ratio of 61.82% as of March 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ADC Therapeutics SA debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how ADC Therapeutics SA's Asset Resilience Ratio has changed over time. See ADCT net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ADC Therapeutics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ADC Therapeutics SA (ADCT) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $231.10 Million | 61.82% |
| Total Liquid Assets | $231.10 Million | 61.82% |
Asset Resilience Insights
- Very High Liquidity: ADC Therapeutics SA maintains exceptional liquid asset reserves at 61.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ADC Therapeutics SA Industry Peers by Asset Resilience Ratio
Compare ADC Therapeutics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC |
Biotechnology | 91585.83% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 2.34% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
Annual Asset Resilience Ratio for ADC Therapeutics SA (None–None)
The table below shows the annual Asset Resilience Ratio data for ADC Therapeutics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the Chi… Read more